pharmarisc.com
antitrust Archives - Pharma Risc
http://www.pharmarisc.com/tag/antitrust
Legal compliance risks and corporate governance issues facing pharma companies. Cash-Payment Rule Needed For Pay-For-Delay Litigation Frenzy. February 13, 2014. By José P Sierra. The fallout from the Supreme Court’s decision last Summer in. Antitrust “rule of reason” approach can and should be applied to non-cash reverse payment settlements. [Read more.]. Plaintiff’s Bar and FTC Launch Antitrust Offensive Against Patent Settlements. September 25, 2013. By José P Sierra. August 12, 2013. By José P Sierra.
pharmarisc.com
class action Archives - Pharma Risc
http://www.pharmarisc.com/category/class-action
Legal compliance risks and corporate governance issues facing pharma companies. Cash-Payment Rule Needed For Pay-For-Delay Litigation Frenzy. February 13, 2014. By José P Sierra. The fallout from the Supreme Court’s decision last Summer in. Antitrust “rule of reason” approach can and should be applied to non-cash reverse payment settlements. [Read more.]. Using A Company’s “Intrinsic” Value In Defending Securities Fraud Suits. October 28, 2013. By José P Sierra. A recent securities class action lawsuit f...
pharmarisc.com
antitrust Archives - Pharma Risc
http://www.pharmarisc.com/category/antitrust
Legal compliance risks and corporate governance issues facing pharma companies. Cash-Payment Rule Needed For Pay-For-Delay Litigation Frenzy. February 13, 2014. By José P Sierra. The fallout from the Supreme Court’s decision last Summer in. Antitrust “rule of reason” approach can and should be applied to non-cash reverse payment settlements. [Read more.]. Plaintiff’s Bar and FTC Launch Antitrust Offensive Against Patent Settlements. September 25, 2013. By José P Sierra. August 12, 2013. By José P Sierra.
pharmarisc.com
whistleblowing Archives - Pharma Risc
http://www.pharmarisc.com/category/whistleblowing
Legal compliance risks and corporate governance issues facing pharma companies. Nursing Home “Worthless Services” Theory Can’t Support FCA Liability. September 25, 2014. By José P Sierra. Government Slams Ranbaxy Again Over Plant In India. January 28, 2014. By José P Sierra. Filed Under: false claims act. Tagged With: false claims act. Will GSK’s Incentive Compensation And Speaker Program Initiatives Set The Tone For 2014? January 8, 2014. By José P Sierra. November 7, 2013. By José P Sierra. Suit involv...
pharmarisc.com
Anti-kickback Archives - Pharma Risc
http://www.pharmarisc.com/category/anti-kickback
Legal compliance risks and corporate governance issues facing pharma companies. Nursing Home “Worthless Services” Theory Can’t Support FCA Liability. September 25, 2014. By José P Sierra. Will GSK’s Incentive Compensation And Speaker Program Initiatives Set The Tone For 2014? January 8, 2014. By José P Sierra. J&J to Pay $2.2 Billion To End Long-Standing Investigations By Feds. November 7, 2013. By José P Sierra. September 6, 2013. By José P Sierra. August 29, 2013. By José P Sierra. August 21, 2013.
pharmarisc.com
First Amendment Archives - Pharma Risc
http://www.pharmarisc.com/category/first-amendment
Legal compliance risks and corporate governance issues facing pharma companies. FDA’s Social Media Guidance and the First Amendment – the Next Frontier. August 21, 2014. By José P Sierra. Now that Pharmarisc is back up and running, what better topic to discuss than the one that started this blog in the first place back in December, 2012 – the FDA’s incursion into manufacturers’ free speech rights. However, instead of focusing on. Et al, lets take a look at the FDA’s June, 2014 Guidance re. Medtronic InFU...
pharmarisc.com
Off-label Archives - Pharma Risc
http://www.pharmarisc.com/category/off-label-2
Legal compliance risks and corporate governance issues facing pharma companies. FDA’s Social Media Guidance and the First Amendment – the Next Frontier. August 21, 2014. By José P Sierra. Now that Pharmarisc is back up and running, what better topic to discuss than the one that started this blog in the first place back in December, 2012 – the FDA’s incursion into manufacturers’ free speech rights. However, instead of focusing on. Et al, lets take a look at the FDA’s June, 2014 Guidance re. January 8, 2014.
pharmarisc.com
class action Archives - Pharma Risc
http://www.pharmarisc.com/tag/class-action
Legal compliance risks and corporate governance issues facing pharma companies. Cash-Payment Rule Needed For Pay-For-Delay Litigation Frenzy. February 13, 2014. By José P Sierra. The fallout from the Supreme Court’s decision last Summer in. Antitrust “rule of reason” approach can and should be applied to non-cash reverse payment settlements. [Read more.]. Using A Company’s “Intrinsic” Value In Defending Securities Fraud Suits. October 28, 2013. By José P Sierra. A recent securities class action lawsuit f...
pharmarisc.com
patent/life cycle Archives - Pharma Risc
http://www.pharmarisc.com/category/patentlife-cycle
Legal compliance risks and corporate governance issues facing pharma companies. The Patent Troll Threat To Pharmaceutical Companies. March 11, 2014. By José P Sierra. Filed Under: patent/life cycle. Tagged With: patent/life cycle. Supreme Court Rejects Design Defect End-Around Of Pliva v Mensing Ruling. June 26, 2013. By José P Sierra. In the last week of the its 2012-13 term, the Supreme Court spurned the First Circuit’s attempt to circumvent the Court’s 2011 decision in. PLIVA, Inc. v. Mensing. Yesterd...